Physician profile
Joshua G Gibbs
NPI 1427195734
$5,077.99
in general payments reported to CMS, 2019-2025
15 companies · $657 in 2025
The $657 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $308 · 2021: $644 · 2022: $694 · 2023: $537 · 2024: $373 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.80 |
| Education | $226.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,385.10 | 2020-2025 | Dupixent |
| Phadia US INC. | $1,325.99 | 2019 | |
| Genzyme Corporation | $716.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $552.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $312.36 | 2019-2024 | Fasenra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $213.04 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $211.98 | 2019-2025 | |
| Csl Behring | $144.14 | 2021-2024 | Hizentra |
| Leo Pharma INC. | $45.06 | 2022 | |
| Pfizer INC. | $41.84 | 2021-2025 | |
| Uswm, LLC | $34.89 | 2021 | |
| Alk-Abello, INC | $34.50 | 2020-2025 | Odactra, Ragwitek, Grastek |
| Galderma Laboratories, L.P. | $23.43 | 2025 | Nemluvio |
| Genentech USA, INC. | $23.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.